Roche CEO: As­sume 'sharp de­cline' in Covid-re­lat­ed sales next year

The bio­phar­ma gi­ant Roche missed its mark on sales goals for its lat­est earn­ings re­port.

The mas­sive Swiss phar­ma saw its sales to date go up by around 2%, hold­ing ex­change rates con­stant, but that in­crease was marked by a 6% de­cline this quar­ter, along with the en­trance of biosim­i­lar com­pe­ti­tion and the de­cline of Covid-19 drug sales.

And while the com­pa­ny does plan on see­ing Covid-19 drug sales get­ting bet­ter some­time soon, out­go­ing CEO Sev­erin Schwan doesn’t ex­pect it to last in­to next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER